Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis
- PMID: 21730278
- DOI: 10.1345/aph.1Q024
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis
Abstract
Background: Long-acting glucagon-like peptide-1 receptor agonists (LA-GLP-1RAs) may deliver additional therapeutic benefits over other available incretin-based therapies.
Objective: To pool results of randomized controlled trials comparing the efficacy and safety of maximum dose LA-GLP-1RAs (liraglutide, exenatide once weekly) with exenatide twice daily and dipeptidyl-peptidase-IV inhibitors in patients with type 2 diabetes.
Methods: We searched PubMed, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, EMBASE (all from inception-December 2010), and abstracts presented at the American Diabetes Association Scientific Sessions in 2009 and 2010 to identify English-language reports of studies of at least 24 weeks' duration. The primary endpoint was mean change in hemoglobin A(1c) (A1C) from baseline to study endpoint. Weighted mean differences or odds ratios and their 95% confidence intervals for each outcome relative to control were calculated as appropriate.
Results: A1C was reduced favoring LA-GLP-1RAs compared with exenatide twice daily and sitagliptin (weighted mean difference [WMD] -0.47% [95% CI -0.69 to -0.25] and WMD -0.60% [95% CI -0.75 to -0.45], respectively). Odds ratios greater than 1 favored LA-GLP-1RAs for reaching the A1C target goal of less than 7%. Fasting plasma glucose (FPG) was reduced and favored the LA-GLP-1RA-based regimens. Exenatide demonstrated significantly greater reductions in postprandial glucose (PPG) after the morning and evening meals, compared with LA-GLP-1RAs. Body weight was reduced similarly between LA-GLP-1RAs and exenatide, but favored LA-GLP-1RAs in the sitagliptin comparator trials. LA-GLP-1RA therapy was not associated with severe hypoglycemia or acute pancreatitis. Compared with exenatide twice daily, vomiting was reduced significantly with LA-GLP-1RAs (OR 0.55; 95% CI 0.34 to 0.89); there was a trend toward decreased nausea (OR 0.58; 95% CI 0.32 to 1.06) and no difference in the incidence of diarrhea (OR 1.03; 95% CI 0.67 to 1.58).
Conclusions: Compared with other incretin-based therapies, LA-GLP-1RAs produce greater improvement in A1C and FPG. They provide lesser effect on PPG, similar reduction in body weight, and result in a potentially favorable adverse event profile compared with exenatide twice daily.
Similar articles
-
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
-
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].Med Clin (Barc). 2014 Sep;143 Suppl 2:23-7. doi: 10.1016/S0025-7753(14)70105-8. Epub 2014 Oct 15. Med Clin (Barc). 2014. PMID: 25437462 Review. Spanish.
-
Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.Endocr Pract. 2013 Jan-Feb;19(1):64-72. doi: 10.4158/EP12232.OR. Endocr Pract. 2013. PMID: 23186975
-
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.Pharmacology. 2010;86(1):44-57. doi: 10.1159/000314690. Epub 2010 Jul 12. Pharmacology. 2010. PMID: 20616619 Review.
-
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845. Expert Opin Investig Drugs. 2008. PMID: 18491986 Review.
Cited by
-
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.Front Endocrinol (Lausanne). 2023 Feb 1;14:1085799. doi: 10.3389/fendo.2023.1085799. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36843578 Free PMC article. Review.
-
Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.Cardiovasc Diabetol. 2020 Oct 9;19(1):172. doi: 10.1186/s12933-020-01148-8. Cardiovasc Diabetol. 2020. PMID: 33036617 Free PMC article.
-
Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.Aging Dis. 2019 Dec 1;10(6):1311-1319. doi: 10.14336/AD.2019.0303. eCollection 2019 Dec. Aging Dis. 2019. PMID: 31788342 Free PMC article. Review.
-
Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist.J Vet Med Sci. 2018 Oct 10;80(10):1515-1523. doi: 10.1292/jvms.18-0306. Epub 2018 Aug 31. J Vet Med Sci. 2018. PMID: 30175725 Free PMC article.
-
Long-term effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension: results from the PROLOGUE study.Oncotarget. 2017 Dec 6;8(67):111979-111997. doi: 10.18632/oncotarget.22959. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340105 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical